Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Inclusion Criteria: